Effect of Various Doses of Rosuvastatin in the Treatment of Elderly Patients with Unstable Angina Pectoris

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2022 Feb 17

PMID 35173877

Authors

Jingyun Fang

Xueli Zhang

Affiliations

Soon will be listed here.

Abstract

Objectives: This prospective study aimed to explore the effects of various doses of rosuvastatin on the hemodynamic changes, highly sensitive C-reactive protein (hs-CRP) and interleukin-6 (IL-6) levels in elderly patients with unstable angina pectoris.

Methods: One-hundred and six elderly patients with unstable angina pectoris were enrolled and divided into group A (n=55) and group B (n=51). Under the same treatment for angina pectoris, patients in groups A and B were administered with 5 mg and 10 mg of rosuvastatin orally once every night, respectively. The two groups were compared in terms of hemorheology, coagulation indices and immune reaction (serum hs-CRP and IL-6 levels), changes of clinical indices, electrocardiograph (ECG), therapeutic effect, and incidence of adverse reactions. Serum hs-CRP and IL-6 levels were detected by ELISA method, and their correlation was analyzed by Pearson method.

Results: Whole blood viscosity at high cut (BVH), whole blood viscosity at low cut (BVL), plasma viscosity (PV), and erythrocyte sedimentation rate (ESR), immunoglobulin index, and the hs-CRP and IL-6 levels decreased in both groups after treatment and were lower in group B than in group A (<0.05). Prothrombin time (PT) and activated partial thromboplastin time (APTT) increased, while fibrinogen (FIB) decreased in both groups after treatment (<0.05). Group B was superior to group A in the onset times of myocardial ischemia and angina pectoris, the total duration of myocardial ischemia, and the total effective rate indicated by ECG (<0.05). No statistical difference was observed in the incidence of adverse reactions between the two groups after treatment (>0.05).

Conclusions: The optimal efficacy of rosuvastatin at 10 mg/day was higher than that of rosuvastatin at 5 mg/day.

Citing Articles

Prescribing Renally Inappropriate Medication to Hospitalized Geriatric Patients in Makkah, Saudi Arabia.

Alqashqri H, Siddiqi A, Albar H, Alfalogy E, Hariri N, Alhindi Y Int J Gen Med. 2024; 17:1755-1764.

PMID: 38706746 PMC: 11070154. DOI: 10.2147/IJGM.S462135.

References

Mintz G, Maehara A, Bui A, Weissman N . Multiple versus single coronary plaque ruptures detected by intravascular ultrasound in stable and unstable angina pectoris and in acute myocardial infarction. Am J Cardiol. 2003; 91(11):1333-5. DOI: 10.1016/s0002-9149(03)00323-0. View

Mierzynski R, Poniedzialek-Czajkowska E, Kimber-Trojnar Z, Leszczynska-Gorzelak B, Oleszczuk J . Anticoagulant therapy in pregnant patients with metabolic syndrome: a review. Curr Pharm Biotechnol. 2014; 15(1):47-63. DOI: 10.2174/1389201015666140330194049. View

Kones R . Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective. Drug Des Devel Ther. 2011; 4:383-413. PMC: 3023269. DOI: 10.2147/DDDT.S10812. View

Irace C, Carallo C, Scavelli F, Esposito T, De Franceschi M, Tripolino C . Influence of blood lipids on plasma and blood viscosity. Clin Hemorheol Microcirc. 2013; 57(3):267-74. DOI: 10.3233/CH-131705. View

Ucak A, Onan B, Guler A, Sahin M, Kilickaya O, Oztas E . Rosuvastatin, a new generation 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, reduces ischemia/reperfusion-induced spinal cord tissue injury in rats. Ann Vasc Surg. 2011; 25(5):686-95. DOI: 10.1016/j.avsg.2011.02.024. View

Gach O, Nys M, Deby-Dupont G, Chapelle J, Lamy M, Pierard L . Acute neutrophil activation in direct stenting: comparison of stable and unstable angina patients. Int J Cardiol. 2005; 112(1):59-65. DOI: 10.1016/j.ijcard.2005.09.010. View

Stalker T, Lefer A, Scalia R . A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol. 2001; 133(3):406-12. PMC: 1572789. DOI: 10.1038/sj.bjp.0704070. View

Micallef M, Garg M . Beyond blood lipids: phytosterols, statins and omega-3 polyunsaturated fatty acid therapy for hyperlipidemia. J Nutr Biochem. 2009; 20(12):927-39. DOI: 10.1016/j.jnutbio.2009.06.009. View

Jukema R, Ahmed T, Tardif J . Does low-density lipoprotein cholesterol induce inflammation? If so, does it matter? Current insights and future perspectives for novel therapies. BMC Med. 2019; 17(1):197. PMC: 6824020. DOI: 10.1186/s12916-019-1433-3. View

10.

Pelter M, Loranger D, Kozik T, Kedia A, Ganchan R, Ganchan D . Among Unstable Angina and Non-ST-Elevation Myocardial Infarction Patients, Transient Myocardial Ischemia and Early Invasive Treatment Are Predictors of Major In-hospital Complications. J Cardiovasc Nurs. 2015; 31(4):E10-9. PMC: 4896865. DOI: 10.1097/JCN.0000000000000310. View

11.

Hong M, Mintz G, Lee C, Kim Y, Lee S, Song J . Comparison of coronary plaque rupture between stable angina and acute myocardial infarction: a three-vessel intravascular ultrasound study in 235 patients. Circulation. 2004; 110(8):928-33. DOI: 10.1161/01.CIR.0000139858.69915.2E. View

12.

Hiraiwa K, Miller S, Ngan D, Vasilescu D, Hackett T, Kinose D . Statins reduce the burden of ambient particulate matter and inflammatory cells within the lung tissues of smokers with and without COPD. Eur Respir J. 2017; 49(1). DOI: 10.1183/13993003.01689-2016. View

13.

Pasterkamp G, van Lammeren G . Pleiotropic effects of statins in atherosclerotic disease. Expert Rev Cardiovasc Ther. 2010; 8(9):1235-7. DOI: 10.1586/erc.10.107. View

14.

Yan W, Song Y, Zhou L, Jiang J, Yang F, Duan Q . Immune Cell Repertoire and Their Mediators in Patients with Acute Myocardial Infarction or Stable Angina Pectoris. Int J Med Sci. 2017; 14(2):181-190. PMC: 5332848. DOI: 10.7150/ijms.17119. View

15.

Abdalla Abbas M, Guenther A, Galantucci S, Fawi G, Comi G, Kwan J . Microbial risk factors of cardiovascular and cerebrovascular diseases: potential therapeutical options. Open Neurol J. 2008; 2:20-4. PMC: 2577933. DOI: 10.2174/1874205X00802010020. View

16.

Barter M, Hui W, Lakey R, Catterall J, Cawston T, Young D . Lipophilic statins prevent matrix metalloproteinase-mediated cartilage collagen breakdown by inhibiting protein geranylgeranylation. Ann Rheum Dis. 2010; 69(12):2189-98. DOI: 10.1136/ard.2010.129197. View

17.

Nezasa K, TAKAO A, Kimura K, Takaichi M, Inazawa K, Koike M . Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rat. Xenobiotica. 2002; 32(8):715-27. DOI: 10.1080/00498250210144820. View

18.

HAFT J, Mariano D, Goldstein J . Comparison of the histopathology of culprit lesions in chronic stable angina, unstable angina, and myocardial infarction. Clin Cardiol. 1997; 20(7):651-5. PMC: 6655281. DOI: 10.1002/clc.4960200712. View